Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Paclitaxel + PMX-53|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|PMX-53||PMX-53 is a peptide antagonist that inhibits CD88 (C5AR1), eliciting an antitumor response and potentially resulting in tumor growth inhibition when combined with a chemotherapeutic agent (PMID: 30300579).|
|Paclitaxel||Taxol||7-Epipaclitaxel||Antimicrotubule Agent 12 BCL2 Family Inhibitor 6||Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||squamous cell carcinoma||not applicable||Paclitaxel + PMX-53||Preclinical||Actionable||In a preclinical study, PMX-53 treatment enhanced the sensitivity of Taxol (paclitaxel) therapy, leading to a synergistic effect and resulting in inhibition of cell proliferation and tumor growth in a syngeneic mouse model of poorly differentiated squamous cell carcinoma (PMID: 30300579).||30300579|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|